Ultromics secures £23.7m Series B funding led by Blue Venture Fund to advance AI cardiac imaging
The Series B round was led by the Blue Venture Fund to accelerate the deployment of artificial intelligence in echocardiography.
Ultromics develops artificial intelligence powered software that automates echocardiogram analysis to aid in the diagnosis of cardiovascular disease. The company spun out from the University of Oxford and works alongside the National Health Service.
Oxford based health technology company Ultromics has secured £23.7m in a Series B funding round. The investment was led by the Blue Venture Fund, with additional participation from Optum Ventures, GV, and existing backer Oxford Sciences Innovation.
The capital will be used to accelerate the deployment of the company artificial intelligence platform for echocardiograms, aiming to improve patient outcomes and increase diagnostic efficiency across healthcare systems.
The latest financing brings significant backing from United States based venture capital funds, positioning the company to expand its technology footprint internationally and enhance early detection pathways for heart disease.
From the founder
"Echocardiograms uploaded to the cloud and analyzed by artificial intelligence are set to revolutionize cardiac disease treatment pathways by helping more people understand their risk of heart disease earlier and with greater accuracy,"
Ross Upton
CEO and co-founder at Ultromics
Investor perspective
"Cardiovascular disease is the leading cause of morbidity and mortality in the United States, and Ultromics offers groundbreaking AI solutions for more accurate diagnosis,"
Emir Sandhu
Managing Director, Blue Venture Fund
Use of funds
- 01Expand into international markets
